Skip to main content
TipRanks
Go Ultimate75% OFF

RaySearch Laboratories AB (RAY.B) AI Stock Analysis

3 Followers
SE:RAY.B

RaySearch Laboratories AB

(Nasdaq OMX AB:RAY.B)

Select Model
Rating:66Neutral
Price Target:SEK 180.00▲(0.67% Upside)
Action:reiterated
Date:11/04/26

RaySearch earns a solid above-average score driven primarily by its strong financial foundation: durable double-digit margins, return on equity above 22%, low leverage and free cash flow that has grown every year since 2021 to SEK 402m. The latest earnings call reinforces the operating story with record quarterly sales, sharply higher order intake and a healthy backlog, although margin pressure from an unusual hardware mix, negative quarterly free cash flow and a demanding full-year EBIT target are near-term concerns. The main drag on the score is technical: the stock trades well below all key moving averages with an RSI near oversold levels, pointing to persistent selling pressure. Valuation at a 26.8x P/E is reasonable given the quality of the business and is supplemented by a 2.4% dividend yield, but slowing revenue growth remains the key challenge to watch.

Positive Factors
Recurring revenue and sales growthRecord quarterly sales and a meaningful recurring support base indicate broad customer adoption and continuing revenue visibility. Support income can make the business more resilient than one-off license sales, while ongoing growth supports investment in product development and market expansion.
Negative Factors
Margin pressure from hardware mixThe sharp margin decline shows that revenue growth does not automatically translate into comparable earnings growth. Hardware-heavy sales and related cost pressure can dilute the economics of the software model, while management’s full-year margin target remains dependent on an exceptionally strong quarter.

RaySearch Laboratories AB (RAY.B) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%SE:RAY.B-15.08%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 596.08M
Dividend Yield
2.24%
Average Volume (3M)
157.93K
Price to Earnings (P/E)
29.7
Beta (1Y)
0.77
Revenue Growth
3.16%
EPS Growth
-5.78%
Country
Sweden
Employees
464
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

RaySearch Laboratories AB Business Overview & Revenue Model

Company Description

RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vas...

How the Company Makes Money

RaySearch primarily makes money by licensing its oncology software to clinics and healthcare providers and then charging ongoing fees tied to software upkeep and expansion. Key revenue streams typically include: (1) Software license revenue from sell...

RaySearch Laboratories AB Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-9.24%|Next Earnings Date:Aug 13, 2026
Earnings Call SentimentPositive

The call was predominantly positive, supported by record Q3 sales, strong order intake, U.S. momentum, strategic customer wins, expanding RayCare adoption, substantial backlog and strong financial flexibility. However, license sales declined, margins were pressured by an unusually high hardware mix, free cash flow was negative, RayCare deal conversion remains gradual, reimbursement-related delays persist, and the full-year EBIT target requires an exceptionally strong fourth quarter.

Positive Updates

Broad Platform Reach and Patient Impact
RaySearch has four software platforms—RayStation, RayCare, RayIntelligence and RayCommand—480 employees across 31 nationalities, 26 industrial partners, and 1,248 clinics in 54 countries using RayStation. The company's software has been used to treat over 11 million cancer patients.

Negative Updates

Quarterly Growth Fluctuation
Management noted a slight decline in the Q3 portion of its recent performance trend, although it still expects growth for the full year of 2026.

Company Guidance

RaySearch expects growth to continue for the full year of 2026 and also expects a very strong end of 2026, with Q4 traditionally its strongest quarter; management said it will be “a stellar Q4” to achieve the full year EBIT margin target of at least 25%, which “remains within reach,” is “not a given” but “reasonable,” and excludes costs related to the long-term incentive program introduced in the second quarter this year. Management expects a few more RayCare orders this year, said RayCare will contribute in 2027, expects customer receivables to remain at the same high numbers in the next quarter but not increase further, and expects sales and marketing costs to be on about the same level in the next quarter as in this.

RaySearch Laboratories AB Financial Statement Overview

Summary

A strong, improving financial profile. Revenue has roughly doubled since 2021 (SEK 642m to SEK 1.34bn) and the company moved from losses to a SEK 227.8m net profit, with net margin near 17% and operating margin around 21% TTM. The balance sheet is conservative, with debt-to-equity cut from 0.89 to 0.46 and return on equity above 22%. Cash generation is the standout: operating cash flow of SEK 424.9m (about 32% of revenue, roughly twice net income) and free cash flow rising every year since 2021 to SEK 402m. Offsetting this, growth has decelerated from over 30% in 2022 to low single digits in the latest twelve months, operating margin has eased, equity and total assets declined in the most recent period, and a sharp drop in capitalized development spending flatters current free cash flow.

Income Statement

76Positive

Balance Sheet

78Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.33B1.34B1.19B1.02B843.65M641.67M
Gross Profit903.20M951.40M1.09B915.58M748.66M591.28M
EBITDA545.10M612.80M571.25M405.94M340.85M197.36M
Net Income204.70M227.80M203.51M81.57M23.78M-47.31M
Balance Sheet
Total Assets1.82B1.99B2.09B1.95B1.88B1.74B
Cash, Cash Equivalents and Short-Term Investments158.30M407.30M462.74M343.68M160.27M102.53M
Total Debt406.00M394.80M471.93M529.36M555.39M561.40M
Total Liabilities1.01B1.01B1.21B1.22B1.22B1.09B
Stockholders Equity804.80M985.30M876.71M735.23M657.16M628.31M
Cash Flow
Free Cash Flow401.70M358.90M267.69M246.60M125.28M-17.06M
Operating Cash Flow424.90M387.00M485.23M455.93M356.78M238.16M
Investing Cash Flow-241.50M-228.10M-217.54M-209.33M-231.50M-237.63M
Financing Cash Flow-349.70M-179.60M-159.78M-56.35M-72.49M-72.23M

RaySearch Laboratories AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price178.80

Price Trends

50DMA182.87Negative
100DMA187.32Negative
200DMA191.40Negative

Market Momentum

MACD-3.21Positive
RSI45.68Neutral
STOCH69.30Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:RAY.B, the sentiment is Neutral. The current price of 178.80 is below the 20-day moving average (MA) of 185.20, below the 50-day MA of 182.87, and below the 200-day MA of 191.40, indicating a bearish trend. The MACD of -3.21 indicates Positive momentum. The RSI at 45.68 is Neutral, neither overbought nor oversold. The STOCH value of 69.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:RAY.B.

RaySearch Laboratories AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:RAY.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B74OutperformSEK 63.88B100.1230.26%0.70%13.94%5.70%
SE:SUSSE:SUS73OutperformSEK 2.93B27.33――4.52%53.01%
SE:RAY.BSE:RAY.B66NeutralSEK 6.13B29.7022.61%2.24%3.16%-5.78%
SE:CRAD.BSE:CRAD.B64NeutralSEK 867.81M18.2613.23%0.39%-8.76%103.87%
SE:PAXSE:PAX61NeutralSEK 1.54B-302.47-1.22%―34.05%-144.96%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:MNTCSE:MNTC51NeutralSEK 475.32M-25.18-15.00%―11.18%60.51%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%SE:RAY.BSE:PAXSE:CRAD.BSE:SECT.BSE:MNTCSE:SUSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:RAY.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:RAY.BRaySearch Laboratories AB Class B178.80-37.13-17.20%
SE:PAXPaxman AB66.004.006.45%
SE:CRAD.BC-Rad AB Class B25.70-8.89-25.71%
SE:SECT.BSectra AB Class B327.4046.6416.61%
SE:MNTCMentice AB16.903.6027.07%
SE:SUSSurgical Science Sweden AB57.40-12.20-17.53%

RaySearch Laboratories AB Corporate Events

RaySearch Reports Record Sales and Strong U.S. Growth

Nov 3, 2026

RaySearch Laboratories develops radiation-oncology software, including RayStation and RayCare, with a global focus on adaptive and proton therapy. The company reported record quarterly net sales and strong U.S. performance, while expanding collaborat...

RaySearch Sets Date for Q3 2026 Interim Report and Webcast

Oct 22, 2026

RaySearch Laboratories AB is a Stockholm-based medical technology company specializing in innovative software for cancer treatment. Its core products include the RayStation treatment planning system and the RayCare oncology information system, comple...

RaySearch Joins IAEA’s Rays of Hope to Boost Global Radiotherapy Access

Sep 28, 2026

RaySearch Laboratories AB, a Swedish medtech firm focused on oncology software, develops systems that support treatment planning, clinical workflow, analytics, and treatment control for cancer clinics worldwide. The company’s products, including RayS...

RaySearch Highlights Integrated Automation and Analytics Suite at ASTRO 2026

Sep 24, 2026

RaySearch Laboratories, a Stockholm-based medical technology firm focused on oncology software such as RayStation and RayCare, is broadening its integrated platform for cancer care with advanced analytics and automation tools. Its global customer bas...

RaySearch expands U.S. footprint as California clinic goes live with integrated RayCare and TrueBeam

Sep 17, 2026

RaySearch Laboratories AB has achieved a new clinical milestone with the go-live of its RayCare oncology information system and RayStation treatment planning software at Advanced Radiation Therapeutics, a new freestanding radiation therapy center wit...

RaySearch and Accuray Deepen Partnership to Drive Adaptive Radiation Therapy

Sep 11, 2026

RaySearch Laboratories AB and U.S.-based Accuray Incorporated have signed a definitive agreement to expand their collaboration around online adaptive radiation therapy. The deal will integrate RaySearch’s RayStation treatment planning and RayCare wor...

RaySearch Balances Weaker Q2 Earnings With Strong Orders and Strategic Investments

Aug 13, 2026

RaySearch Laboratories reported a mixed second quarter, with order intake rising 23 percent to SEK 296 million while net sales fell 11 percent and operating profit dropped 23 percent, pressured mainly by delayed U.S. orders. Despite lower earnings an...

RaySearch wins USD 5 million in new U.S. RayStation orders

Aug 10, 2026

RaySearch Laboratories has secured nine new orders for its RayStation treatment planning system from U.S. customers at the start of the third quarter, with a combined value of about USD 5 million, most of which will be recognized as revenue in the cu...

RaySearch expands UNC proton therapy planning with advanced RayStation deployment

Aug 7, 2026

RaySearch Laboratories AB has secured an order from the University of North Carolina School of Medicine for additional RayStation licenses, expanding the U.S. institution’s long-standing use of the treatment planning system. The new deployment will e...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026